Viridian Therapeutics Revenue vs. Net Income
| VRDN Stock | USD 27.87 0.03 0.11% |
Total Revenue | First Reported 2013-03-31 | Previous Quarter 70.6 M | Current Value 132 K | Quarterly Volatility 9.7 M |
Macro event markers
Profitability analysis for Viridian Therapeutics is expressed through margins and return ratios. The information is based on reported accounting data. Metrics track how income relates to core financial drivers over time. Profitability data is presented without directional implication.
Viridian | Build portfolio with Viridian Stock |
Revenue Breakdown by Segment
World Market Map.
Macro event markers
Earnings Segment Revenue Breakdown for Viridian Therapeutics Snapshot
Earnings estimates are a standard input for assessing forward-looking performance context. These figures serve as informational inputs within a broader research framework.
Earnings Share -3.32 | Revenue Per Share | Quarterly Revenue Growth 0.833 | Return On Assets | Return On Equity |
For Viridian Therapeutics, market value and book value represent two distinct lenses on the same underlying business. Viridian Therapeutics' market capitalization is 2.83 B. At P/B 4.8, Viridian Therapeutics trades at a significant premium to book value. Enterprise value stands at 2.14 B. Where intrinsic value falls relative to market price and book value helps frame the analytical picture. Together, market value, book value, and intrinsic value form a multi-dimensional view. This dataset reflects observed data and is not advisory in nature.
Distinguishing between Viridian Therapeutics' value and market price helps frame analytical expectations. For Viridian Therapeutics, key inputs include a P/B ratio of 4.8, ROE of -49.16%, and revenue of 70.85 M. By contrast, Viridian Therapeutics market price reflects the level where buyers and sellers transact.
Viridian Therapeutics Net Income vs. Revenue Fundamental Analysis
Peer comparison models estimate Viridian Therapeutics's intrinsic positioning within its sector. Viridian Therapeutics lands at #4 in revenue compared to key competitors. It is rated below average in net income compared to key competitors . Comparative financial data indicate that Total Revenue is shifting by roughly 4.76%. Looking back, Viridian Therapeutics posted Total Revenue of 70.85 Million in the previous fiscal year. Earnings-based multiples benchmark Viridian Therapeutics's market valuation.Viridian Revenue vs. Competition
Viridian Therapeutics lands at #4 in revenue compared to key competitors. Market size based on revenue of Health Care industry is at this time estimated at about 1.61 Billion. Viridian Therapeutics holds roughly 70.85 Million in revenue claiming about 4% of equities under Health Care sector.
Viridian Net Income vs. Revenue
Revenue is income that a firm generates from business activities such as rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Viridian Therapeutics |
| = | 70.85 M |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Viridian Therapeutics |
| = | -342.6 M |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Viridian Net Income Comparison
Viridian Therapeutics is currently under evaluation in net income compared to key competitors.
Viridian Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Viridian Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Viridian Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Viridian Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Viridian Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | End Of Year Estimate | ||
| Accumulated Other Comprehensive Income | 447 K | 469.4 K | |
| Operating Income | -363.4 M | -345.2 M | |
| Income Before Tax | -342.6 M | -325.5 M | |
| Total Other Income Expense Net | 20.8 M | 21.8 M | |
| Net Loss | -342.6 M | -325.5 M | |
| Income Tax Expense | -243 M | -230.8 M | |
| Net Loss | -116.9 M | -111 M | |
| Net Interest Income | 22.5 M | 23.6 M | |
| Interest Income | 27.4 M | 28.8 M | |
| Net Loss | -342.6 M | -325.5 M | |
| Non Operating Income Net Other | 5.4 M | 5.7 M | |
| Change To Netincome | 22.7 M | 20.2 M | |
| Net Loss | -4.04 | -4.24 | |
| Income Quality | 0.81 | 0.57 | |
| Net Income Per E B T | 1.16 | 1.02 |
Viridian Profitability Driver Comparison
Understanding Viridian Therapeutics' profitability drivers is essential for assessing the sustainability of its earnings. Unexpected events such as tax policy changes, commodity price shocks, or economic downturns can materially alter the profit outlook and affect long-term investment returns.
Earnings Estimation Breakdown
The forward EPS consensus for Viridian Therapeutics stands at -1.0433, compiled from analyst models tracking Viridian Therapeutics' revenue, margin, and guidance trends. The estimate range spans from -1.25 to -0.94, capturing uncertainty around the projection. This figure is derived from a 12-month earnings base and strips out one-time items for comparability.Last Reported EPS
-1.25 Lowest | Expected EPS | -0.94 Highest |
Earnings Projection Consensus
The spread between Viridian Therapeutics' estimated fair value and its market price encodes a directional signal: narrow spreads suggest efficient pricing; wide spreads suggest a potential catalyst or mispricing. Analysts use this gap to identify entry and exit points, though the estimate itself carries model risk. Factor in liquidity, sector context, and macro environment before acting on this comparison.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2026 | Current EPS (TTM) | |
| 18 | 88.5% | -1.08 | -1.0433 | -3.32 |
Earnings per Share Projection vs Actual
The actual EPS reported by Viridian Therapeutics reflects real earnings performance verified through its financial statements. The expected EPS consensus for Viridian Therapeutics is the result of analyst modeling and represents the market's pre-event benchmark. Weighted share count is used to normalize EPS across periods where the number of outstanding shares changes.Estimated Months Earnings per Share
Income investors tracking Viridian Therapeutics rely on EPS as a measure of earnings coverage for the dividend. A consistent EPS growth trajectory suggests management has both the intent and capacity to increase shareholder distributions over time. For a rounded view, compare EPS against free cash flow yield and the dividend payout ratios of sector peers.Quarterly Analyst Estimates and Surprise Metrics
For investors monitoring Viridian Therapeutics, earnings surprise data provides a historical record of how the market has repriced the stock after each quarterly report. Surprise direction and magnitude together determine whether a post-earnings move is likely to be sustained. Analyst EPS estimates evolve through the quarter based on guidance revisions and new sector information.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2026-03-05 | 2025-12-31 | -0.9558 | -1.08 | -0.1242 | 12 | ||
2025-11-05 | 2025-09-30 | -0.9532 | -0.34 | 0.6132 | 64 | ||
2025-08-06 | 2025-06-30 | -1 | -1.0 | 0.0 | 0 | ||
2025-05-06 | 2025-03-31 | -1.1 | -0.869 | 0.231 | 21 | ||
2025-02-25 | 2024-12-31 | -1.0442 | -0.81 | 0.2342 | 22 | ||
2024-11-11 | 2024-09-30 | -1.06 | -1.1546 | -0.0946 | 8 | ||
2024-08-08 | 2024-06-30 | -0.89 | -1.02 | -0.13 | 14 | ||
2024-05-08 | 2024-03-31 | -1.1 | -0.79 | 0.31 | 28 | ||
2024-02-27 | 2023-12-31 | -1 | -1.35 | -0.35 | 35 | ||
2023-11-13 | 2023-09-30 | -1.27 | -1.09 | 0.18 | 14 | ||
2023-08-08 | 2023-06-30 | -1.29 | -1.27 | 0.02 | 1 | ||
2023-05-09 | 2023-03-31 | -1.02 | -1.61 | -0.59 | 57 | ||
2023-03-08 | 2022-12-31 | -0.73 | -1.13 | -0.4 | 54 | ||
2022-11-14 | 2022-09-30 | -1.02 | -0.86 | 0.16 | 15 | ||
2022-08-15 | 2022-06-30 | -0.9 | -1.06 | -0.16 | 17 | ||
2022-05-12 | 2022-03-31 | -1.08 | -0.98 | 0.1 | 9 | ||
2022-03-10 | 2021-12-31 | -0.9 | -1.32 | -0.42 | 46 | ||
2021-11-04 | 2021-09-30 | -1.47 | -1.25 | 0.22 | 14 | ||
2021-08-11 | 2021-06-30 | -1.52 | -2.21 | -0.69 | 45 | ||
2021-05-06 | 2021-03-31 | -0.76 | -2.91 | -2.15 | 282 | ||
2021-03-25 | 2020-12-31 | -0.61 | -5.31 | -4.7 | 770 | ||
2020-11-10 | 2020-09-30 | -1.99 | -1.5 | 0.49 | 24 | ||
2020-08-05 | 2020-06-30 | -2.47 | -1.8 | 0.67 | 27 | ||
2020-05-07 | 2020-03-31 | -2.88 | -2.7 | 0.18 | 6 | ||
2020-03-11 | 2019-12-31 | -3.78 | -4.65 | -0.87 | 23 | ||
2019-11-07 | 2019-09-30 | -4.44 | -5.4 | -0.96 | 21 | ||
2019-08-07 | 2019-06-30 | -5.59 | -4.35 | 1.24 | 22 | ||
2019-05-08 | 2019-03-31 | -5.16 | -5.7 | -0.54 | 10 | ||
2019-03-13 | 2018-12-31 | -4.62 | -4.95 | -0.33 | 7 | ||
2018-11-07 | 2018-09-30 | -4.76 | -4.35 | 0.41 | 8 | ||
2018-08-07 | 2018-06-30 | -4.35 | -4.35 | 0.0 | 0 | ||
2018-05-09 | 2018-03-31 | -3.66 | -2.7 | 0.96 | 26 | ||
2018-03-14 | 2017-12-31 | -4.76 | -4.35 | 0.41 | 8 | ||
2017-11-08 | 2017-09-30 | -5.9 | -4.05 | 1.85 | 31 | ||
2017-08-11 | 2017-06-30 | -7.05 | -5.1 | 1.95 | 27 | ||
2017-05-10 | 2017-03-31 | -3.6 | -9.0 | -5.4 | 150 | ||
2017-03-24 | 2016-12-31 | -3.45 | -3.45 | 0.0 | 0 | ||
2016-08-15 | 2016-06-30 | -41.62 | -51.75 | -10.13 | 24 | ||
2016-05-16 | 2016-03-31 | -63 | -58.5 | 4.5 | 7 | ||
2016-03-16 | 2015-12-31 | -81 | -63.0 | 18.0 | 22 | ||
2015-11-12 | 2015-09-30 | -83.25 | -87.75 | -4.5 | 5 | ||
2015-08-12 | 2015-06-30 | -87.75 | -74.25 | 13.5 | 15 | ||
2015-05-14 | 2015-03-31 | -81 | -101.25 | -20.25 | 25 | ||
2015-03-30 | 2014-12-31 | -87.75 | -387.0 | -299.25 | 341 | ||
2014-11-14 | 2014-09-30 | -11.25 | -96.75 | -85.5 | 760 |
Use Viridian Therapeutics in pair-trading
Pair analysis around Viridian Therapeutics matters because it can turn one security idea into a more market-neutral structure. This framework is most useful when investors want to hedge directional moves caused by sector headlines or broad market pressure.
Viridian Therapeutics Pair Trading
Viridian Therapeutics Pair Trading Analysis
Correlation analysis provides context to find suitable substitutes for Viridian Therapeutics during tax-loss harvesting periods. Selling Viridian Therapeutics at a loss and immediately repurchasing it would violate IRS wash-sale rules, so a correlated replacement asset is required to maintain portfolio.
Measuring the statistical correlation of Viridian Therapeutics against other instruments provides context for understanding portfolio diversification. A correlation near zero implies that Viridian Therapeutics provides genuine diversification benefits, while high positive correlations suggest redundant exposures.
Hedging context for Viridian Therapeutics can be developed through Correlation analysis and pair trading analysis. The view can be extended across sectors or other related groups.Use Investing Themes to Complement your Viridian Therapeutics position
Viridian Therapeutics operates in Healthcare/Biotechnology at 2.83 Billion market cap - a thematic view expands this smaller-cap position into a broader portfolio concept. Viridian Therapeutics 2.83 Billion smaller-cap footprint in Biotechnology aligns sector exposure with portfolio construction goals rather than adding an isolated Healthcare position.
Did You Try This Idea?
Run Aggressive Defence Thematic Idea Now
Aggressive Defence
Macroaxis small cap, aggressive-outlook picks designed for investors that are willing to accept higher levels of risk to hedge exposure to above-average market volatility. The Aggressive Defence theme has 50 constituents at this time.
Investors can hold the Aggressive Defence Theme as a long-term basket or actively trade individual constituents to capture short-term price movement.
| View All Next | Launch |